nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.12.2014 | short review

Contribution of the vascular bone marrow niche to leukemia progression

verfasst von: Jasmin Wellbrock, Walter Fiedler, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Leukemia arises from leukemic stem cells, which reside within the bone marrow occupying two different stem cells niches: the endosteal and the vascular niche. The maintenance of leukemic stem cells requires complex regulation mediated by many intrinsic and extrinsic signals provided by their niche cells. The interaction of leukemic and endothelial cells can occur either via direct contact through cell adhesion molecules such as selectins or integrins or signals can be transmitted by chemokines or cytokines of which stromal cell-derived factor 1 represents the most studied. Experimental studies provide evidence that targeting molecules involved in the interaction of leukemic and endothelial cells might represent a promising therapeutic target. Indeed, first clinical trials considering this concept are currently under investigation.

Vorheriger Artikel ASCO 2014: news, hopes, hypes?

Nächster Artikel Angiogenesis inhibition, hypoxia, and targeting the bone marrow microenvironment in multiple myeloma: new strategies and targets

Dick JE. Stem cell concepts renew cancer research. Blood. 2008;112:4793–807.PubMedCrossRef

Doan PL, Chute JP. The vascular niche: home for normal and malignant hematopoietic stem cells. Leukemia. 2012;26:54–62.PubMedCrossRef

Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870–5.PubMed

Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240–5.PubMed

Dilly SA, Jagger CJ. Bone marrow stromal cell changes in haematological malignancies. J Clin Pathol. 1990;43:942–6.PubMedCentralPubMedCrossRef

Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. 2011;29:591–9.PubMedCrossRef

Mohle R, Bautz F, Rafii S, Moore MA, Brugger W, Kanz L. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood. 1998;91:4523–30.PubMed

Rombouts EJ, Pavic B, Lowenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood. 2004;104:550–7.PubMedCrossRef

Juarez J, Dela Pena A, Baraz R, Hewson J, Khoo M, Cisterne A, et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia. 2007;21:1249–57.PubMedCrossRef

10.

Liesveld JL, Bechelli J, Rosell K, Lu C, Bridger G, Phillips G, 2nd, et al. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res. 2007;31:1553–63.PubMedCentralPubMedCrossRef

11.

Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113:6215–24.PubMedCentralPubMedCrossRef

12.

Stamatopoulos B, Meuleman N, De Bruyn C, Pieters K, Mineur P, Le Roy C, et al. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments. Haematologica. 2012;97:608–15.PubMedCentralPubMedCrossRef

13.

Herrmann H, Cerny-Reiterer S, Sadovnik I, Winter V, Blatt K, Rabitsch W, et al. Identification of Novel Surface Markers and Targets in Neoplastic Stem Cells in AML and CML: a Flow-Gene-Flow Screen Approach. Blood (ASH Annual Meeting Abstracts). 2010;116:3382.CrossRef

14.

Smith-Berdan S, Nguyen A, Hassanein D, Zimmer M, Ugarte F, Ciriza J, et al. Robo4 cooperates with CXCR4 to specify hematopoietic stem cell localization to bone marrow niches. Cell Stem Cell. 2011;8:72–83.PubMedCentralPubMedCrossRef

15.

Smith-Berdan S, Schepers K, Ly A, Passegue E, Forsberg EC. Dynamic expression of the Robo ligand Slit2 in bone marrow cell populations. Cell Cycle. 2012;11:675–82.PubMedCrossRef

16.

ter Huurne M, Figdor CG, Torensma R. Hematopoietic stem cells are coordinated by the molecular cues of the endosteal niche. Stem Cells Dev. 2010;19:1131–41.PubMedCrossRef

17.

Mazo IB, Gutierrez-Ramos JC, Frenette PS, Hynes RO, Wagner DD, von Andrian UH. Hematopoietic progenitor cell rolling in bone marrow microvessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1. J Exp Med. 1998;188:465–74.PubMedCentralPubMedCrossRef

18.

Winkler IG, Barbier V, Nowlan B, Jacobsen RN, Forristal CE, Patton JT, et al. Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance. Nat Med. 2012;18:1651–7.PubMedCrossRef

19.

Pezeshkian B, Donnelly C, Tamburo K, Geddes T, Madlambayan GJ. Leukemia mediated endothelial cell activation modulates leukemia cell susceptibility to chemotherapy through a positive feedback loop mechanism. PLoS One. 2013;8:e60823.PubMedCentralPubMedCrossRef

20.

Krause DS, Lazarides K, Lewis JB, von Andrian UH, Van Etten RA. Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche. Blood. 2014;123:1361–71.PubMedCrossRef

21.

Wicklein D, Schmidt A, Labitzky V, Ullrich S, Valent P, Schumacher U. E- and p-selectins are essential for repopulation of chronic myelogenous and chronic eosinophilic leukemias in a scid mouse xenograft model. PLoS One. 2013;8:e70139.PubMedCentralPubMedCrossRef

22.

Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med. 2004;10:64–71.PubMedCrossRef

23.

Williams DA, Rios M, Stephens C, Patel VP. Fibronectin and VLA-4 in haematopoietic stem cell-microenvironment interactions. Nature. 1991;352:438–41.PubMedCrossRef

24.

Rettig MP, Ansstas G, DiPersio JF. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia. 2012;26:34–53.PubMedCentralPubMedCrossRef

25.

Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med. 2003;9:1158–65.PubMedCrossRef

26.

Magyarosy E, Sebestyen A, Timar J. Expression of metastasis associated proteins, CD44v6 and NM23-H1, in pediatric acute lymphoblastic leukemia. Anticancer Res. 2001;21:819–23.PubMed

27.

Zarcone D, De Rossi G, Tenca C, Marroni P, Mauro FR, Cerruti GM, et al. Functional and clinical relevance of CD44 variant isoform expression on B-cell chronic lymphocytic leukemia cells. Haematologica. 1998;83:1088–98.PubMed

28.

Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12:1167–74.PubMedCrossRef

29.

Charrad RS, Li Y, Delpech B, Balitrand N, Clay D, Jasmin C, et al. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nat Med. 1999;5:669–76.PubMedCrossRef

30.

Wellbrock J, Fiedler W. Clinical experience with antiangiogenic therapy in leukemia. Curr Cancer Drug Targets. 2011;11:1053–68.PubMedCrossRef

Titel: Contribution of the vascular bone marrow niche to leukemia progression
verfasst von: Jasmin Wellbrock
Walter Fiedler, MD
Publikationsdatum: 01.12.2014
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-014-0149-5

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Lung cancer: ASCO 2014 update

Is there a role for angiogenesis inhibition in prostate cancer?

ASCO 2014: highlights in breast cancer

International MDS Working Groups: a model of success to improve diagnosis and treatment in rare diseases: 10-year jubilee of the Austrian MDS platform

Post ASCO update 2014: head and neck cancer

Angiogenesis